NBY Novabay Pharmaceuticals Inc.
- 0 P/E
- 17.38 P/S
- 4.03 P/B
- -0.387 EPS
- -2,638.06% Cash ROIC
- 4.98 Cash Ratio
- 0.00 / N/A % Dividend
- 200,668.00 Avg. Vol.
- 25.77M Shares
- 48.6M Market Cap.
NovaBay Pharmaceuticals Inc., a clinical stage biotechnology company, engages in developing proprietary and patented topical Aganocide compounds for the treatment and prevention of various infections without causing bacterial resistance. Its Aganocide compounds are synthetic anti-infective product candidates with equivalent activity to the active antimicrobial molecules generated within white bloo...
Business Wire (press release) - Jul 16, 2014
Wall Street Journal - Jul 3, 2014
Crazy Joys - Jul 13, 2014
MarketWatch - Jun 26, 2014
Techsonian (press release) - Jul 21, 2014
Wall Street Journal - Jul 2, 2014
Wall Street Journal - Jul 10, 2014
Wall Street Journal - Jul 18, 2014
Reuters Key Development - May 20, 2014
Reuters Key Development - Mar 20, 2014